Evidence map›Paper›PMID 26422386›Full record

ArticlePloS one2015

In vitro Characterization of the Rapid Cytotoxicity of Anticancer Peptide HPRP-A2 through Membrane Destruction and Intracellular Mechanism against Gastric Cancer Cell Lines.

Jing Zhao, Xueyu Hao, Dong Liu, Yibing Huang, Yuxin Chen

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Multisite aggregation of p53 and implications for drug rescue.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jing ZhaoKey Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, Jilin University, Changchun, China; School of Life Sciences, Jilin University, Changchun, China.
Xueyu HaoKey Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, Jilin University, Changchun, China; School of Life Sciences, Jilin University, Changchun, China.
Dong LiuKey Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, Jilin University, Changchun, China; School of Life Sciences, Jilin University, Changchun, China.
Yibing HuangKey Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, Jilin University, Changchun, China; School of Life Sciences, Jilin University, Changchun, China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, China.
Yuxin ChenKey Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, Jilin University, Changchun, China; School of Life Sciences, Jilin University, Changchun, China; National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, China.
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, HPRP-A2, a synthetic 15-mer cationic peptides with all D-amino acids, effectively inhibited the survival of gastric cell lines in a dose-dependent manner. Gastric tumor cells killing by HPRP-A2 involves a rapid collapse of the membrane integrity and intracellular pathways. Propidium iodide (PI) and lactate dehydrogenase (LDH) assays demonstrated that one-hour treatment with HPRP-A2 led to membrane permeability changes of BGC-823 cells in a dose-dependent manner. Moreover, HPRP-A2 induced apoptosis in BGC-823 cells involves a marked increase in generation of reactive oxygen species (ROS),caspase-3, -8 and -9 activation, a reduction of mitochondrial membrane potential (MMP), and cell cycle arrest in G1 phase. In addition to its inherent cytotoxicity, HPRP-A2 synergized strongly with doxorubicin (DOX) to enhance the efficacy of killing gastric tumor cells in vitro. We believe that HPRP-A2 with all D-amino acids could be a potent candidate of anticancer therapeutics, especially in combination therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCaspasesCell Line, TumorCell Membrane PermeabilityDoxorubicinG1 PhaseHumansMembrane Potential, MitochondrialMitochondriaPeptidesReactive Oxygen SpeciesStomach NeoplasmsCaspasesDoxorubicinPeptidesReactive Oxygen Species

Identifiers

PMID26422386
PMCPMC4589244
OpenAlexW2237855526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.